Clinical trial
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted…
NCT03498521 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT03498521 |
|---|---|
| Title | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site |
| Official title | A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum… |
| Acronym | CUPISCO |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Foundation Medicine Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer of Unknown Primary Site |
| Intervention type | Drug |
| Interventions | Alectinib, Vismodegib, Ipatasertib, Olaparib, Erlotinib, Bevacizumab, Vemurafenib, Cobimetinib, Trastuzumab Subcutaneous (SC), Pertuzumab and 8 more |
| Enrollment | 529 |
| Start date | Jul 10, 2018 |
| Primary completion | Feb 14, 2023 |
| Completion | Nov 7, 2024 |
| First posted | Apr 13, 2018 |
| Last update posted | Nov 19, 2025 |
| Countries | Australia, Austria, Brazil, Bulgaria, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France and 21 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: